Trial
NCT02128230
UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Arkansas
Collaborators
Amgen
Condition
Multiple Myeloma
Intervention
myPRS
Why stopped
Low enrollment and Futility as determined by Amgen's Carfilzomib NASCR program.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-06-22